GTHA – GeneThera, Inc.
Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
GeneThera and Leading Italian Research Institute Finalize Collaboration Agreement on Mad-Cow and Other Animal Diseases – In depth view.
We want to tell you about a company that is unique in the world of biotechnology and we want to link it to a problem that is incredibly high profile: Mad Cow Disease. The official name for Mad Cow Disease is bovine spongiform encephalopathy which is the original Mad Cow Disease before it mutated.
The original disease was transmitted through feed. The mutated strain is transferred from animal to animal and is known as BSAE or bovine spongiform amyloid encephalopathy. This is a mutation of significance and has the potential increase the transmission threat.
That having been said, this company is not exclusively about Mad Cow Disease but that will be our initial focus because this is where the action is right now — in this company and in the world — and there is a serious and significant story here that we will unfold for you over the next few weeks.
Ask yourself, why have you not heard about a serious United States biotechnology company working on Mad Cow Disease?
USA Today has reported:
Possibly due to pressure from large agribusiness, the United States has drastically cut back on the number of cows inspected for the BSE (USA Today, August 4, 2006) Also, the U.S. is prohibiting the sale of test kits that detect BSE. Sixty-five nations have full or partial restrictions on importing U.S. beef products because of concerns that U.S. testing lacks sufficient rigor. As a result, exports of U.S. beef declined from $3.8 billion in 2003, before the first mad cow was detected in the US, to $1.4 billion in 2005. (USA Today, August 4, 2006.)
To make a long story short, no companies, no universities, no one in the United States can use animals for testing and trials for Mad Cow Disease other than the United States Department of Agriculture (USDA). And they simply are not testing effectively or in any significant quantities. It is estimated that they are testing 40,000 animals a year which is less than one tenth of one percent. USA Today notes the tests are ineffective and inconclusive and we will examine that further.
The point of significance here the USDA is testing a miniscule number of animals, their tests are not considered to be effective and they deny anyone, ANYONE ELSE the right to test for Mad Cow Disease in this country.
One company has found a way to continue their work in this area: Leave the United States for Clinical Trials!
For Dr. Milici and GeneThera that’s where Italy comes in. It is a match made in heaven. Dr. Milici is Italian and came to the United States in his twenties. In Italy every cow that is slaughter MUST be tested for Mad Cow Disease. Dr. Milici is ready for clinical trials and this is where his trials will take place. He will be able to conduct clinical trials on 2,000 animals a day.
This is serious, unique, and incredibly important work that has stumbled and faltered in the United States principally due to policital impediments.
Dr. Milici and his brave company, GeneThera, Inc. have found a way to move forward in spite of these federal impediments.
Stay tuned for this very important story with more twists and turns than a Colorado Mountain switchback. Also, and very importantly, we will examine other focuses this company has.
About GeneThera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER),(www.bs.izs.it), offers a broad range of services in the Public Veterinary sectors in particular, Food Safety to the Veterinary Services, Breeders and Consumers. Its functions today can be described as those of a Technical-Scientific Body providing services as required of it by national and regional law. At the present, IZSLER employs over 600 persons, 90 of them are graduated scientists (veterinarians, biologists and chemists). On a regional basis (Lombardia and Emilia Romagna), IZSLER performs diagnosis for a variety of viral infectious diseases of ruminants, pigs, horses, poultry and other species of economic interest (rabbits, fishes, bees….), and microbiological and chemical analysis on foodstuffs of animal origin destined for human consumption and on food resources for animals.
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC: was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.